Small Cap Pharma Stock seen a Huge Traded Volume, Near Breakout
In the fast-paced world of stock trading,
pharmaceutical companies often emerge as some of the most lucrative investment
options. With their potential for groundbreaking medical advancements,
expanding global reach, and ever-increasing demand for healthcare products,
pharma stocks have become a favorite among investors.
A small cap pharmaceutical Stock “Marksans Pharma” is grabbing investor attention.
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
The stock price surge 7 % during today’s
trading session and closed at 81.05 with an eye-catching traded volume of 18.93
M which is almost 7.5X the average volume of 10 days.
Milestone
Since incorporation in 2001, Marksans Pharma
has undergone various phases of transformation, consolidation, mergers and
acquisitions. From its initial identity of being a wholly owned subsidiary of
Glenmark Pharmaceuticals Ltd., the organization has grown from
strength-to-strength to make a mark in the global pharmaceutical space.
2009 -Marksans Pharma established itself as a global
player
2008 -Acquired Bells, Sons & Co. (Druggists)
Ltd.
Acquired
Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty
Ltd.
2003 - Spun-off into a separate entity - Glenmark
Laboratories Ltd.
Changed its name to "Marksans Pharma Ltd"
2001 - Marksans was incorporated as a wholly owned
subsidiary of Glenmark Pharmaceuticals Ltd.
Global Presence
In order to expand its global footprint and to consolidate
its operations and product offerings, Marksans had entered into strategic
tie-ups and acquired key players in the major global markets.
Some of our major activities include:
- Tie-ups with leading global
MNC’s for offering CRAMS
- Setting up of specialized and
state-of-the-art soft gel manufacturing facilities
- Entering into long-term
out-licensing agreements with leading pharmaceutical companies
- Setting up our own front-ends
across major global markets
- Establishing
a strong marketing presence in domestic markets

Comments
Post a Comment